NovaBay Pharmaceuticals

Equities

NBY

US66987P3001

Delayed Nyse 04:10:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.1047 USD -5.86% Intraday chart for NovaBay Pharmaceuticals -23.69% -48.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M MT
New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc.. CI
NovaBay Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Fiscal Year 2023 CI
New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. for $1.07 million. CI
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network CI
Transcript : NovaBay Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q3 Revenue $3.3M, vs. Street Est of $3.55M MT
Novabay Pharmaceuticals, Inc. Announces Commercial Launch of Avenova Allograft CI
NovaBay to Commercialize BioStem's Amniotic Tissue Allograft MT
NovaBay Pharmaceuticals, Inc. Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova®? Allograft CI
Ladenburg Thalmann Cuts Price Target on NovaBay Pharmaceuticals to $3.80 From $6, Maintains Buy Rating MT
Transcript : NovaBay Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q2 Revenue $4.6M, vs. Street Est of $3.7M MT
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023 CI
Novabay Pharmaceuticals, Inc. Approves to Elect Mijia Wu as Director CI
NovaBay Pharmaceuticals, Inc. Announces DERMAdoctor's KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to Be Featured on QVC at a Special Price CI
Wall Street Set to Open Higher; Investors Look to Powell Speech for Fed Action Hints MT
US Futures Trend Higher Pre-Bell Ahead of Powell Speech MT
Top Premarket Gainers MT
Transcript : NovaBay Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 11, 2023
Chart NovaBay Pharmaceuticals
More charts
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells consumer products for the eyecare and skincare markets. The Company's lead product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have antimicrobial properties as it removes foreign material, such as microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with its form of hypochlorous acid and is cleared by the United States Food and Drug Administration (FDA) for sale in the United States. Its other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress and the i-Chek. Avenova Spray is available both over-the-counter and as a prescription. Avenova Spray is also available at optometrists and ophthalmologists offices; at national pharmacy chains across all over 50 states, and through its Partner Pharmacy Program.
Sector
-
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1047 USD
Average target price
3.5 USD
Spread / Average Target
+3,242.95%
Consensus
  1. Stock
  2. Equities
  3. Stock NovaBay Pharmaceuticals - Nyse
  4. News NovaBay Pharmaceuticals
  5. NovaBay Pharmaceuticals : Ladenburg Thalmann Adjusts NovaBay Pharmaceuticals PT to $2.20 From $1.90, Maintains Buy Rating